Insulin icodec

Awiqli

1,050UNITS/1.5ML InjectionUnited StatesMarketedAuthorised 26 Mar 2026

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Insulin icodec

Awiqli

1,050UNITS/1.5ML InjectionUnited StatesMarketedAuthorised 26 Mar 2026

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

AwiqliItaly · Soluzione iniettabile in penna pre-riempita · Novo Nordisk A/S

Awiqli 700 eenheden/ml oplossing voor injectie in voorgevulde penNetherlands · Oplossing voor injectie · Novo Nordisk A.S.

Documents

The official texts, at the regulator.

Register entryFDA

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions · Added 11 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Insulin icodec
Strength: 1,050UNITS/1.5ML
Dosage form: Injection
Route: Subcutaneous
Register: United States (FDA)
Status: Marketed
Status in the register: Licensed / Rx
Authorised: 26 Mar 2026
Registration: BLA 761326
Marketing authorisation holder: Novo Nordisk Inc.
Procedure: 351(a)
Supply: Rx